Mantle Cell Lymphoma (MCL) is typically an aggressive, rare, form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone”. The abnormal B Lymphocytes start to collect in the lymph nodes or body organs. They can then form tumors and begin to cause problems within the lymphatic system or the organ where they are growing.
About 85% of patients with Mantle Cell Lymphoma have a characteristic genetic lesion known as reciprocal translocation which is a major cause of MCL. In this genetic change, the short segment of one chromosome is moved to another chromosome. This change is considered a driver in the behaviour of MCL, which likely works together with other genetic defects to cause MCL.
The Mantle cell Lymphoma market report covers emerging drugs, current treatment practices, Mantle cell Lymphoma market share of the individual therapies, current and forecasted Mantle cell Lymphoma Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Mantle cell Lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Mantle cell Lymphoma Market Key Facts
According to Leukemia and Lymphoma Society, MCL patients represent only about six per cent (6%) of all new cases of NHL in the United States.
As per a study titled “Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A
comparative study between Texas and National SEER areas” conducted by Michael Wang et.al., from 1995 to 2013, there were 2,000 to 5,000 newly diagnosed MCL patients in Texas and SEER areas. Age-adjusted MCL incidence was 0.91 per 100,000 persons per year in Texas and 1.01 in SEER areas.
According to a study titled “Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France” conducted by Christophe Leux et.al., over the period of 2002-2006, the age standardised incidence rate of MCL (per 100,000) was 0.72 in men and 0.17 in women
Visit For Sample Pages:
Key Benefits of Mantle cell Lymphoma Market Report
Mantle cell Lymphoma market report provides an in-depth analysis of Mantle cell Lymphoma Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Mantle cell Lymphoma market report will help in developing business strategies by understanding the Mantle cell Lymphoma Market trends & developments, key players and future market competition that will shape and drive the Mantle cell Lymphoma market in the upcoming years.
The Mantle cell Lymphoma market report covers Mantle cell Lymphoma current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Mantle cell Lymphoma market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Mantle cell Lymphoma market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Mantle cell Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Mantle cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
The Mantle cell Lymphoma epidemiology section covers insights about historical and current Mantle cell Lymphoma patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Mantle cell Lymphoma Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mantle cell Lymphoma market or expected to get launched in the market during the study period. The analysis covers Mantle cell Lymphoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Mantle cell Lymphoma market is expected to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2020–2030. Companies across the globe are working towards the development of new treatment therapies for mantle cell lymphoma.
Expected launch of emerging therapies such as KTE-X19 (Gilead Sciences), Parsaclisib (Incyte Corporation), TGR-1202 + Ublituximab (TG Therapeutics), Orelabrutinib (ICP-022, InnoCare Pharma Tech) and others will significantly impact the MCL market during the forecast period (2020-2030).
key players in the therapeutic market of Mantle cell Lymphoma includes includes-
InnoCare Pharma Tech and many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Mantle cell Lymphoma Competitive Intelligence Analysis
4. Mantle cell Lymphoma Market Overview at a Glance
5. Mantle cell Lymphoma Disease Background and Overview
6. Mantle cell Lymphoma Patient Journey
7. Mantle cell Lymphoma Epidemiology and Patient Population
8. Mantle cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Mantle cell Lymphoma Unmet Needs
10. Key Endpoints of Mantle cell Lymphoma Treatment
11. Mantle cell Lymphoma Marketed Products
12. Mantle cell Lymphoma Emerging Therapies
13. Mantle cell Lymphoma Seven Major Market Analysis
14. Attribute Analysis
15. Mantle cell Lymphoma Market Outlook (7 major markets)
16. Mantle cell Lymphoma Access and Reimbursement Overview
17. KOL Views on the Mantle cell Lymphoma Market.
18. Mantle cell Lymphoma Market Drivers
19. Mantle cell Lymphoma Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Mantle Cell Lymphoma Epidemiology Forecast to 2030
DelveInsight’s Mantle Cell Lymphoma Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Mantle Cell Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Mantle Cell Lymphoma Pipeline Insights, 2020
Mantle Cell Lymphoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Mantle Cell Lymphoma market.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States